These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35339647)

  • 1. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
    Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
    Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
    Sahin I; George A; Seyhan AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
    Urbanski LM; Leclair N; Anczuków O
    Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
    Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
    Roy Burman D; Das S; Das C; Bhattacharya R
    Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
    Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
    BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
    Bessa C; Matos P; Jordan P; Gonçalves V
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA splicing dysregulation and the hallmarks of cancer.
    Bradley RK; Anczuków O
    Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
    Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.
    Bemmo A; Dias C; Rose AA; Russo C; Siegel P; Majewski J
    PLoS One; 2010 Aug; 5(8):e11981. PubMed ID: 20700505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
    Mercatante DR; Sazani P; Kole R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Splicing and Cancer.
    Wang E; Aifantis I
    Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entropy measures quantify global splicing disorders in cancer.
    Ritchie W; Granjeaud S; Puthier D; Gautheret D
    PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA splicing: a dual-edged sword for hepatocellular carcinoma.
    Kashyap A; Tripathi G; Tripathi A; Rao R; Kashyap M; Bhat A; Kumar D; Rajhans A; Kumar P; Chandrashekar DS; Mahmood R; Husain A; Zayed H; Bharti AC; Kashyap MK
    Med Oncol; 2022 Aug; 39(11):173. PubMed ID: 35972700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape with RNA-Binding Proteins.
    Porto FW; Daulatabad SV; Janga SC
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31390792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.
    Rizzacasa B; Morini E; Pucci S; Murdocca M; Novelli G; Amati F
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.
    Renshaw J; Orr RM; Walton MI; Te Poele R; Williams RD; Wancewicz EV; Monia BP; Workman P; Pritchard-Jones K
    Mol Cancer Ther; 2004 Nov; 3(11):1467-84. PubMed ID: 15542786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splice variants of MDM2 in oncogenesis.
    Rosso M; Okoro DE; Bargonetti J
    Subcell Biochem; 2014; 85():247-61. PubMed ID: 25201199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.